What is Remynd?
Remynd is a clinical-stage biopharmaceutical firm dedicated to developing novel therapeutic treatments for debilitating conditions such as Alzheimer's disease, diabetes, and epilepsy. The company leverages a proprietary drug discovery platform designed to identify unique mechanisms of action, therapeutic targets, and first-in-class small molecules. Remynd's lead program, ReS19-T, an investigational compound for Alzheimer's, has entered clinical trials, showing promise in restoring synaptic plasticity in preclinical models. Additionally, the company is advancing ReS39, a diabetes treatment aimed at enhancing endogenous insulin production. Remynd also operates a Contract Research Organization (CRO) specializing in CNS disorders, serving a global clientele.
How much funding has Remynd raised?
Remynd has raised a total of $29.2M across 1 funding round:
Series B
$29.2M
Series B (2021): $29.2M with participation from PMV Groupe, BNP Paribas Fortis, FPIM, Korys Investments, and KU Leuven
Key Investors in Remynd
PMV Groupe
PMV Groupe is an investment firm that supports the growth and development of companies, likely focusing on strategic capital deployment.
BNP Paribas Fortis
BNP Paribas Fortis, founded in 1848 and headquartered in Belgium, is a banking institution offering a variety of financial services and solutions to customers.
FPIM
FPIM is an investment entity that provides financial backing to companies, likely with a focus on strategic growth initiatives.
What's next for Remynd?
With the recent influx of major strategic investment, Remynd is poised for significant advancements in its therapeutic development. The company is expected to prioritize the progression of its Alzheimer's and diabetes programs through clinical trials, aiming to validate the efficacy of ReS19-T and ReS39. Further exploration of its drug discovery platform for other CNS disorders and mitochondrial dysfunction-related diseases is also anticipated. The substantial backing will likely fuel expanded research and development efforts, potentially leading to new drug candidates and strengthening Remynd's position in the biopharmaceutical sector.
See full Remynd company page
